January 20, 2017
Avacta expects to license Affimer technology in 2017
Avacta expects to license Affimer technology in 2017, and it says this year is very optimistic for its shareholders.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
January 20, 2017
Abzena nets $300 million for its ThioBridge technology
Abzena has made a deal with a San Diego-based biopharmaceutical company for Abzena’s novel site–specific ThioBridge antibody drug conjugate (ADC) linker technology, which links antibodies and other proteins to drugs. The $300 million worth agreement with the…
January 20, 2017
Cerenis satisfied with Q4 2016, expects good news from clinic in Q1 2017
French company Cerenis Therapeutics has seen some good things happen in the previous period in clinics by finalizing certain studies and getting FDA’s approval to kick some off. Also certain results showed progress and the company has reported solid cash position for the end of the year.
January 20, 2017
Japanese MHLW OK’s Bayer’s cancer drug
Japanese Ministry of Health, Labour and Welfare (MHLW) has granted priority review to Bayer Yakuhin for regorafenib in the second-line…
January 20, 2017
Latvian Olainfarm sales up by 39% year to year, target topped by 6%
According to preliminary consolidated results of Latvian JSC Olainfarm for December 2016, sales of the Groups have reached €10.28 million, which represents an increase by 39% compared to December 2015.
January 19, 2017
FDA approves Allergan’s skin disease drug
U.S. Food and Drug Administration (FDA) has approved Allergan’s Rhofade skin desease cream, a topical treatment of persistent facial erythema (redness)…
January 19, 2017
Anavex secures cash to study Anavex 2-73 for Rett syndrome
Anavex has ensured most of the cash for a U.S. multicentre Phase 2 clinical trial of Rett syndrome treatment Anavex2-73.
January 19, 2017
NeuroVive presents positive preclinical data in hepatocellular cancer at HCC Summit
NeuroVive Pharmaceutical’s abstract with novel preclinical cancer data related to the company’s sanglifehrin-based compounds has been accepted for presentation at…
January 19, 2017
Summit Therapeutics’s R&D adviser becomes COO, President of Research Development
Summit Therapeutics has named its research and development adviser Dr David Roblin as new Chief Operating Officer (COO) and President of Research Development.
January 19, 2017
PledPharma’s Nomination Committee wants board changes
PledPharma’s Nomination Committee has submitted a proposal for a new composition of the Board of Directors for consideration at an…